FRANKFURT, March 20 (Reuters) - Bayer AG shares jumped as much as 9 percent on Friday, following a green light for the German company’s key new drug Xarelto from a U.S. panel, putting it on track to win approval in its largest market.
FRANKFURT, March 20 (Reuters) - Bayer AG shares jumped as much as 9 percent on Friday, following a green light for the German company’s key new drug Xarelto from a U.S. panel, putting it on track to win approval in its largest market.
